Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor and Interleukin 34 in Patients with Chronic Hepatitis C as Serological Fibrosis Markers — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor and Interleukin 34 in Patients with Chronic Hepatitis C as Serological Fibrosis Markers
Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
,
Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
,
Hepatology, Gastroenterology and Infectious Diseases Departments, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
,
Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
,
Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
1 Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
2 Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
3 Hepatology, Gastroenterology and Infectious Diseases Departments, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
4 Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
5 Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
Background: Hepatitis C Virus (HCV) infection is a progressive disease that may result in chronic hepatitis, fibrosis and cirrhosis. Assessment of liver fibrosis is an essential factor in the management of chronic HCV. Objective: To evaluate plasma soluble Urokinase Plasminogen Activator Receptor (sUPAR) and interleukin-34 (IL-34) as serological markers of liver fibrosis in patients with chronic HCV. Methods: This case-control study enrolled 60 chronic HCV patients who were subdivided into three groups of mild, moderate and severe hepatic fibrosis depending on Fibrosis-4 score (FIB-4). Patients were compared with 20 age and sex-matched controls. Plasma sUPAR and IL-34 levels were measured by Enzyme Linked Immunosorbent Assay (ELISA). Results: Plasma sUPAR and IL-34 were significantly increased in HCV patients when compared with controls, and their increase was positively correlated with the progression of hepatic fibrosis. Plasma sUPAR and IL-34 positively correlated with Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT), and negatively correlated with hemoglobin concentration and platelet count. The output data of Receiver Operating Characteristic (ROC) curve to differentiate patients from controls revealed that sUPAR at cut-off > 186.2 ng/L and Area Under Curve (AUC) of 0.944 had (85%) sensitivity and (100%) specificity, and IL-34 at cut off > 16.4 ng/L and AUC of 0.942 had (75%) sensitivity and (100%) specificity. The output data of ROC curve to differentiate severe from mild to moderate hepatic fibrosis patients revealed that sUPAR at cut-off > 510 ng/L and AUC of 0.837 had (80%) sensitivity and (90%) specificity. While IL-34 at cut off > 55.3 ng/L and AUC of 0.844 had (85%) sensitivity and (80%) specificity. Conclusions: Increased plasma levels of sUPAR and IL-34 in chronic HCV patients with liver fibrosis and their increase was parallel to the degree of liver fibrosis. Plasma sUPAR and IL-34 can be used as serological markers of liver fibrosis in chronic HCV patients.
Giuffrè, M., Fouraki, S., Comar, M., Masutti, F. and Crocè, L.S. (2020) The Importance of Transaminases Flares in Liver Elastography. Characterization of the Probability of Liver Fibrosis Overestimation by Hepatitis C Virus-Induced Cytolysis. Microorganisms, 8, 348. https://doi.org/10.3390/microorganisms8030348
Redman, J. and Sterling, R. (2020) Non-Invasive Assessment of Liver Fibrosis. Current Treatment Options in Gastroenterology, 18, 255-269. https://doi.org/10.1007/s11938-020-00285-z
Catanzaro, R., Sciuto, M., Lanzafame, C., Balakrishnan, B. and Marotta, F. (2020) Platelet to Lymphocyte Ratio as a Predictive Biomarker of Liver Fibrosis (on Elastography) in Patients with Hepatitis C Virus (HCV)-Related Liver Disease. Indian Journal of Gastroenterology, 39, 253-260. https://doi.org/10.1007/s12664-020-01038-7
Fallatah, H. (2014) Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology, 2014, Article ID: e357287. https://doi.org/10.1155/2014/357287
Tsochatzis, E., Bruno, S., Isgro, G., Hall, A., Theocharidou, E., Manousou, P., Dhillon, A.P., Burroughs, A.K. and Luong, T.V. (2014) Collagen Proportionate Area Is Superior to Other Histological Methods for Subclassifying Cirrhosis and Determining Prognosis. Journal of Hepatology, 2014, 948-954. https://doi.org/10.1016/j.jhep.2013.12.023
Zhou, K. and Lu, G. (2009) Assessment of Fibrosis in Chronic Liver Diseases. Journal of Digestive Diseases, 10, 7-14. https://doi.org/10.1111/j.1751-2980.2008.00356.x
Sadeghi, A., Amiri, R., Akbarpour, E., et al. (2021) Changes in Liver Fibrosis in Patients with Chronic Hepatitis C after Successful Direct-Acting Antiviral Therapy. International Journal of Clinical Practice, 75, e14145. https://doi.org/10.22541/au.159986388.88453135
Udompap, P., Sukonrut, K., Suvannarerg, V., Pongpaibul, A. and Charatcharoenwitthaya, P. (2020) Prospective Comparison of Transient Elastography, Point Shear Wave Elastography, APRI and FIB-4 for Staging Liver Fibrosis in Chronic Viral Hepatitis. Journal of Viral Hepatitis, 27, 437-448. https://doi.org/10.1111/jvh.13246
Koch, A., Zimmermann, W., Gassler, N., Jochum, C., Weiskirchen, R., Bruensing, J., Buendgens, L., Dückers, H., Bruns, T., Gerken, G., Neumann, U.P., Adams, D.H., Trautwein, C., Canbay, A. and Tacke, F. (2014) Clinical Relevance and Cellular Source of Elevated Soluble Urokinase Plasminogen Activator Receptor (sUPAR) in Acute Liver Failure. Liver International, 34, 1330-1339. https://doi.org/10.1111/liv.12512
Huang, F., Li, Y., Xu, R., Cheng, A., Lv, Y. and Liu, Q. (2020) The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis. Mediators of Inflammation, 2020, Article ID: 7850179. https://doi.org/10.1155/2020/7850179
Ge, Y., Huang, M. and Yao, Y. (2019) Immunomodulation of Interleukin-34 and Its Potential Significance as a Disease Biomarker and Therapeutic Target. International Journal of Biological Sciences, 15, 1835-1845. https://doi.org/10.7150/ijbs.35070
Kawagishi, N., Suda, G., Kimura, M., et al. (2020) High Serum Angiopoietin-2 Level Predicts Non-Regression of Liver Stiffness Measurement-Based Liver Fibrosis Stage after Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology Research, 50, 671-681. https://doi.org/10.1111/hepr.13490
Taneja, S., Tohra, S., Duseja, A., et al. (2016) Noninvasive Assessment of Liver Fibrosis by Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C—An Experience from a Tertiary Care Hospital. Journal of Clinical and Experimental Hepatology, 6, 282-290. https://doi.org/10.1016/j.jceh.2016.08.001
Waked, I., Esmat, G., Elsharkawy, A., et al. (2020) Screening and Treatment Program to Eliminate Hepatitis C in Egypt. New England Journal of Medicine, 382, 1166-1174. https://doi.org/10.1056/NEJMsr1912628
Akdogan, O., Yücel, A., Sargin, Z., Sonmez, C., Yilmaz, G.E. and Ozenirler, S. (2019) Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients with Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker. Journal of Clinical and Experimental Hepatology, 9, 29-33. https://doi.org/10.1016/j.jceh.2018.02.001
Gronbaek, H., Gantzel, R., Laursen, T., Kazankov, K. and Moller, H.J. (2020) Macrophage Markers and Innate Immunity in Cirrhosis. Journal of Hepatology, 73, 1586-1588. https://doi.org/10.1016/j.jhep.2020.07.033
Saraiva, G., do Rosário, N., Medeiros, T., Medeiros, T., Leite, P.E.C., de Souza Lacerda, G., de Andrade, T.G., de Azeredo, E.L., Ancuta, P., Almeida, J.R., Xavier, A.R. and Silva, A.A. (2018) Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C. Mediators of Inflammation, 2018, Article ID: 8578051. https://doi.org/10.1155/2018/8578051
Garnaes, E., Mortensen, C., Hobolth, L., Andersen, O., Nehlin, J. and Moller, S. (2019) Kinetics of the Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Cirrhosis. PLoS ONE, 14, e0220697. https://doi.org/10.1371/journal.pone.0220697
Wang, Y., Cao, W., Gao, Y., Ye, J. and Zou, G.-Z. (2018) Serum Interleukin-34 Level Can Be an Indicator of Liver Fibrosis in Patients with Chronic Hepatitis B Virus Infection. World Journal of Gastroenterology, 24, 1312-1320. https://doi.org/10.3748/wjg.v24.i12.1312
Munoz-Garcia, J., Cochonneau, D., Télétchéa, S., et al. (2021) The Twin Cytokines Interleukin-34 and CSF-1: Masterful Conductors of Macrophage Homeostasis. Theranostics, 11, 1568-1593. https://doi.org/10.7150/thno.50683
Kanto, T. and Yoshio, S. (2017) Hepatitis Action Plan and Changing Trend of Liver Disease in Japan: Viral Hepatitis and Nonalcoholic Fatty Liver Disease. European Journal of Hepato-Gastroenterology, 7, 60-64. https://doi.org/10.5005/jp-journals-10018-1213
Preisser, L., Miot, C., Le Guillou-Guillemette, H., et al. (2014) IL-34 and Macrophage Colony-Stimulating Factor Are Overexpressed in Hepatitis C Virus Fibrosis and Induce Profibrotic Macrophages That Promote Collagen Synthesis by Hepatic Stellate Cells. Hepatology, 60, 1879-1890. https://doi.org/10.1002/hep.27328
Khairy, R., Hmmad, S., Sayed, M., et al. (2020) Serum MicroRNAs as Predictors for Fibrosis Progression and Response to Direct-Acting Antivirals Treatment in Hepatitis C Virus Genotype-4 Egyptian Patients. International Journal of Clinical Practice, 75, e13954. https://doi.org/10.1111/ijcp.13954
Huynh, T., Zhang, J. and Hu, Q. (2018) Hepatitis C Virus Clearance by Direct-Acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. Journal of Clinical and Translational Hepatology, 6, 258-263. https://doi.org/10.14218/JCTH.2018.00014
Abd Elbaser, S., Abdelkader, A. and Afifi, S. (2020) IL-1α and TGF-β1 as Non-Invasive Liver Fibrosis Markers of Chronic Liver Injury among Chronic Liver Diseases Patients in Sharkia Governorate, Egypt. Afro-Egyptian Journal of Infectious and Endemic Diseases, 10, 108-113. https://doi.org/10.21608/aeji.2020.23397.1050
Zaki, N., El-Naggar, A., Ghallab, O., et al. (2017) Anemia in Egyptian Chronic Hepatitis C Patients: Study of the Causes Prior to and during Interferon/Ribavirin versus Sofosbuvir Therapy. World Journal of Pharmaceutical and Medical Research, 3, 20-28.
Shao, N., Zhang, T., Wang, N., et al. (2020) Platelet Indices Significantly Correlate with Liver Fibrosis in HCV-Infected Patients. PLoS ONE, 15, e0227544. https://doi.org/10.1371/journal.pone.0227544
Zayed, R., Omran, D., Mokhtar, D., et al. (2017) Association of Toll-Like Receptor 3 and Toll-Like Receptor 9 Single Nucleotide Polymorphisms with Hepatitis c Virus Infection and Hepatic Fibrosis in Egyptian Patients. The American Journal of Tropical Medicine and Hygiene, 96, 720-726. https://doi.org/10.4269/ajtmh.16-0644
Berres, M., Schlosser, B., Berg, T., et al. (2012) Soluble Urokinase Plasminogen Activator Receptor Is Associated with Progressive Liver Fibrosis in Hepatitis C Infection. Journal of Clinical Gastroenterology, 46, 334-338. https://doi.org/10.1097/MCG.0b013e31822da19d
Udomsinprasert, W., Honsawek, S., Jirathanathornnukul, N., et al. (2016) Elevation of Serum Urokinase Plasminogen Activator Receptor and Liver Stiffness in Postoperative Biliary Atresia. World Journal of Hepatology, 8, 1471-1477. https://doi.org/10.4254/wjh.v8.i33.1471
Shoji, H., Yoshio, S., Mano, Y., et al. (2016) Interleukin-34 as a Fibroblast-Derived Marker of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Scientific Reports, 6, Article No. 28814. https://doi.org/10.1038/srep28814
Baghdadi, M., Ishikawa, K., Endo, H., et al. (2018) Enhanced Expression of IL-34 in an Inflammatory Cyst of the Submandibular Gland: A Case Report. Inflammation and Regeneration, 38, Article No. 12. https://doi.org/10.1186/s41232-018-0069-6